Evolocumab in Patients without a Previous Myocardial Infarction or Stroke
New England Journal of Medicine · 08.01.2026 · 394 (2) · 117-127
DOI: 10.1056/nejmoa2514428 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 08.01.2026. Verfasst von Erin A Bohula und 23 weiteren Autor:innen. Beteiligte Einrichtung: Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Anticholesteremic Agents, Atherosclerosis, Cardiovascular Diseases. Die Arbeit wurde bisher 150-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Amgen.
Themen: Schlaganfall
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston.
- Amgen, Thousand Oaks, CA.
- Cardiology Division, Department of Medical Sciences, University of Turin and Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Turin, Italy.
- Division of Endocrinology and Metabolism, St. Michael's Hospital, University of Toronto, Toronto.
- Instituto do Coracao, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, Universidade de São Paulo, São Paulo.
- Third Department of Internal Medicine-Metabolism and Gerontology, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové and Charles University, Hradec Králové, Czech Republic.
ORCID-Profile: E Magnus Ohman
Förderung
- Amgen
Zitieren
APA
Bohula, E. A., Marston, N. A., Bhatia, A. K., De Ferrari, G. M., Leiter, L. A., Nicolau, J. C., Park, J. G., Kuder, J. F., Murphy, S. A., Walsh, E., Wang, H., Blaha, V., Budaj, A., Cornel, J. H., Goudev, A., Kiss, R. G., Lorenzatti, A. J., Parkhomenko, A., Cyrille, M., …, & VESALIUS-CV Investigators (2026). Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. New England Journal of Medicine, 394(2), 117-127. https://doi.org/10.1056/nejmoa2514428
Vancouver
Bohula EA, Marston NA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, et al. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. New England Journal of Medicine. 2026;394(2):117-127. doi:10.1056/nejmoa2514428
BibTeX
@article{Bohula2026,
author = {Bohula, Erin A and Marston, Nicholas A and Bhatia, Ajay K and De Ferrari, Gaetano M and Leiter, Lawrence A and Nicolau, Jose C and Park, Jeong-Gun and Kuder, Julia F and Murphy, Sabina A and Walsh, Emileigh and Wang, Huei and Blaha, Vladimir and Budaj, Andrzej and Cornel, Jan H and Goudev, Assen and Kiss, Robert Gabor and Lorenzatti, Alberto J and Parkhomenko, Alexander and Cyrille, Marcoli and Paiva da Silva Lima, Gabriel and Ohman, E Magnus and Giugliano, Robert P and Sabatine, Marc S and VESALIUS-CV Investigators, VESALIUS-CV Investigators},
title = {Evolocumab in Patients without a Previous Myocardial Infarction or Stroke},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {2},
pages = {117--127},
doi = {10.1056/nejmoa2514428}
}
EUVIMED